X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Unichem Lab with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 UNICHEM LAB   ACTAVIS
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
ACTAVIS
Dec-14
UNICHEM LAB/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs33417,533-   
Low Rs17410,695-   
Sales per share (Unadj.) Rs146.93,157.2-  
Earnings per share (Unadj.) Rs11.9-394.0-  
Cash flow per share (Unadj.) Rs16.2289.7-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs105.16,847.8-  
Shares outstanding (eoy) m90.84265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.74.5 38.7%   
Avg P/E ratio x21.4-35.8 -59.6%  
P/CF ratio (eoy) x15.748.7 32.2%  
Price / Book Value ratio x2.42.1 117.2%  
Dividend payout %16.80-   
Avg Mkt Cap Rs m23,0733,752,831 0.6%   
No. of employees `0005.721.6 26.3%   
Total wages/salary Rs m2,5580-   
Avg. sales/employee Rs Th2,352.538,865.5 6.1%   
Avg. wages/employee Rs Th450.90-   
Avg. net profit/employee Rs Th190.4-4,850.0 -3.9%   
INCOME DATA
Net Sales Rs m13,346839,495 1.6%  
Other income Rs m192-2,095 -9.2%   
Total revenues Rs m13,538837,400 1.6%   
Gross profit Rs m1,639107,845 1.5%  
Depreciation Rs m390181,781 0.2%   
Interest Rs m2926,479 0.1%   
Profit before tax Rs m1,412-102,511 -1.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-40-   
Extraordinary Inc (Exp) Rs m-35-7,520 0.5%   
Tax Rs m293-5,270 -5.6%   
Profit after tax Rs m1,080-104,760 -1.0%  
Gross profit margin %12.312.8 95.6%  
Effective tax rate %20.75.1 403.2%   
Net profit margin %8.1-12.5 -64.9%  
BALANCE SHEET DATA
Current assets Rs m5,979442,306 1.4%   
Current liabilities Rs m2,432322,571 0.8%   
Net working cap to sales %26.614.3 186.4%  
Current ratio x2.51.4 179.3%  
Inventory Days Days6358 108.7%  
Debtors Days Days6066 91.1%  
Net fixed assets Rs m6,403102,511 6.2%   
Share capital Rs m1820-   
"Free" reserves Rs m9,2930-   
Net worth Rs m9,5481,820,833 0.5%   
Long term debt Rs m230954,152 0.0%   
Total assets Rs m12,8433,336,988 0.4%  
Interest coverage x50.0-2.9 -1,742.4%   
Debt to equity ratio x00.5 4.6%  
Sales to assets ratio x1.00.3 413.1%   
Return on assets %8.6-2.3 -368.2%  
Return on equity %11.3-5.8 -196.7%  
Return on capital %14.3-3.0 -476.1%  
Exports to sales %29.20-   
Imports to sales %6.30-   
Net fx Rs m3,1940-   
CASH FLOW
From Operations Rs m1,119144,158 0.8%  
From Investments Rs m-853-345,168 0.2%  
From Financial Activity Rs m-334193,935 -0.2%  
Net Cashflow Rs m-68-7,076 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare UNICHEM LAB With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare UNICHEM LAB With: PANACEA BIOTECH  J.B.CHEMICALS  ELDER PHARMA  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 20, 2018 09:49 AM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - DISHMAN PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS